


RealRate

PHARMACEUTICAL 2021

Organogenesis Empowering Healing

Organogenesis Holdings Inc. Rank 51 of 409







PHARMACEUTICAL 2021



RealRate

Organogenesis Holdings Inc. Rank 51 of 409

The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 581% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 460% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	174,344
Cost of Goods Sold	87,319
Intangible Assets	59,394
Liabilities, Current	68,217
Liabilities, Non-Current	7,971
Other Assets	688
Other Compr. Net Income	0
Other Expenses	530
Other Liabilities	72,222
Other Net Income	-8,936
Property and Equipment	60,068
Research and Development	20,086
Revenues	338,298
Selling, General and Administrative Expense	203,478

Output Variable	Value in 1000 USD
Assets	294,494
Liabilities	148,410
Expenses	311,413
Stockholders Equity	146,084
Net Income	17,949
Comprehensive Net Income	17,949
Economic Capital Ratio	105%

